|
- GLP-1 DRUG LIRAGLUTIDE MAY PROTECT AGAINST DEMENTIA
PHILADELPHIA, July 30, 2024 — A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial data reported today at the Alzheimer’s Association International Conference® (AAIC®) 2024, in Philadelphia and online
- Older GLP-1 drug shows glimmer of benefit in Alzheimers
A small study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide shows a benefit in patients with Alzheimer's disease
- Elad Gil Plots $1. 5 Billion Fund, Stretching Definition of a . . .
That makes a case for Elad Gil, a prolific investor who made early investments in Perplexity, Harvey, Stripe and Airbnb Gil is raising a fund of around $1 5 billion to back both young and mature startups, according to two people with knowledge on the matter
- Evaluating Liraglutide in Alzheimers Disease (ELAD)
Study Overview Brief Summary This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study in patients with mild Alzheimer's dementia (AD) Patients will be randomised on a 1:1 ratio to receive liraglutide or matching placebo
- GLP-1 Analog Slows Cognitive Decline; Potential Alzheimer . . .
The study author conducted a multicenter, randomized, double-blind, placebo-controlled, phase 2b trial (Effects of the Novel GLP-1 Analogue Liraglutide in Alzheimer’s Disease; ELAD) at 24 clinics throughout the United Kingdom to determine the neuroprotective effects of liraglutide
- Sources: Elad Gil is raising a fund of ~$1. 5B that could grow . . .
Sources: Elad Gil is raising a fund of ~$1 5B that could grow to $2B based on investor interest, making it one of the largest fundraising hauls for a solo GP — Venture capital firms are under pressure to make rapid-fire decisions about big checks in the frenzied world of artificial intelligence investing …
- Promising New Data Support GLP-1s for Dementia Prevention
In the phase 2b ELAD clinical trial, adults with early-stage Alzheimer's disease (AD) taking the GLP-1 receptor agonist liraglutide exhibited slower decline in memory and thinking and
|
|
|